Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DLK-IN-1 is a selective oral active inhibitor of bisleucine zipper kinase (DLK, MAP3K12) with Ki of 3 nM. DLK-IN-1 is active in the Alzheimer's disease model, retains excellent CNS permeability, and after multiple days of administration, its concentration exceeds the concentration required for DLK inhibition in the brain, so it has good tolerance Acceptability.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | 10-14 weeks | $ 523.00 | |
25 mg | 10-14 weeks | $ 1,750.00 | |
50 mg | 10-14 weeks | $ 2,280.00 | |
100 mg | 10-14 weeks | $ 3,270.00 |
Description | DLK-IN-1 is a selective oral active inhibitor of bisleucine zipper kinase (DLK, MAP3K12) with Ki of 3 nM. DLK-IN-1 is active in the Alzheimer's disease model, retains excellent CNS permeability, and after multiple days of administration, its concentration exceeds the concentration required for DLK inhibition in the brain, so it has good tolerance Acceptability. |
Targets&IC50 | DLK:ki:3 nM |
Molecular Weight | 423.43 |
Formula | C20H24F3N5O2 |
CAS No. | 1620574-24-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 62.5 mg/mL (147.60 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
DLK-IN-1 1620574-24-4 DNA Damage/DNA Repair DNA Alkylation DLK IN 1 DLKIN1 inhibitor inhibit